{"id":70893,"date":"2026-07-29T18:40:16","date_gmt":"2026-07-29T10:40:16","guid":{"rendered":"https:\/\/flcube.com\/?p=70893"},"modified":"2026-07-29T18:40:16","modified_gmt":"2026-07-29T10:40:16","slug":"hansoh-pharmaceuticals-b7-h3-adc-risvutatug-rezetecan-hits-primary-endpoint-in-osteosarcoma-phase-iii-trial-validating-gsk-partnership","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70893","title":{"rendered":"Hansoh Pharmaceutical&#8217;s B7-H3 ADC Risvutatug Rezetecan Hits Primary Endpoint in Osteosarcoma Phase III Trial, Validating GSK Partnership"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Hansoh Pharmaceutical<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/3692:HKG\">HKG: 3692<\/a>) announced that its pivotal <strong>Phase III ARTEMIS-011 clinical trial<\/strong> of <strong>Risvutatug Rezetecan (HS-20093)<\/strong> achieved statistical significance for the primary endpoint of <strong>progression-free survival (PFS)<\/strong> in patients with <strong>relapsed or refractory osteosarcoma<\/strong>, representing a major milestone for the company&#8217;s lead antibody-drug conjugate and validating its $1.7 billion partnership with GlaxoSmithKline.<\/p>\n\n\n\n<h2 id=\"h-clinical-trial-results-overview\" class=\"wp-block-heading\">Clinical Trial Results Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Hansoh Pharmaceutical (HKG: 3692)<\/td><\/tr><tr><td><strong>Drug Candidate<\/strong><\/td><td>Risvutatug Rezetecan (HS-20093)<\/td><\/tr><tr><td><strong>Trial ID<\/strong><\/td><td>ARTEMIS-011<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Relapsed\/refractory osteosarcoma (\u22652 prior systemic therapies)<\/td><\/tr><tr><td><strong>Trial Design<\/strong><\/td><td>Randomized Phase III vs. chemotherapy<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>IRC-assessed progression-free survival (PFS)<\/td><\/tr><tr><td><strong>Result<\/strong><\/td><td>Statistically significant and clinically meaningful PFS improvement<\/td><\/tr><tr><td><strong>Secondary Endpoints<\/strong><\/td><td>Overall survival (OS) and investigator-assessed PFS also showed consistent benefits<\/td><\/tr><tr><td><strong>Safety<\/strong><\/td><td>Consistent with previous studies; no new safety signals<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-technology\" class=\"wp-block-heading\">Drug Profile &amp; Technology<\/h2>\n\n\n\n<h3 id=\"h-adc-architecture\" class=\"wp-block-heading\">ADC Architecture<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target:<\/strong> <strong>B7-H3<\/strong> \u2013 tumor-associated antigen overexpressed across multiple solid tumors<\/li>\n\n\n\n<li><strong>Antibody Component:<\/strong> <strong>Fully human anti-B7-H3 monoclonal antibody<\/strong><\/li>\n\n\n\n<li><strong>Payload:<\/strong> <strong>Topoisomerase inhibitor (TOPOi)<\/strong> covalently linked via proprietary conjugation technology<\/li>\n\n\n\n<li><strong>Development Status:<\/strong> Independently developed by Hansoh Pharmaceutical with global intellectual property<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-mechanism-of-action\" class=\"wp-block-heading\">Mechanism of Action<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Targeted Delivery:<\/strong> Antibody directs cytotoxic payload specifically to B7-H3-expressing tumor cells<\/li>\n\n\n\n<li><strong>Bystander Effect:<\/strong> Payload diffusion may kill adjacent tumor cells regardless of B7-H3 expression<\/li>\n\n\n\n<li><strong>Therapeutic Rationale:<\/strong> Exploits high B7-H3 expression in osteosarcoma and other solid tumors while sparing normal tissues<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-global-development-portfolio\" class=\"wp-block-heading\">Global Development Portfolio<\/h2>\n\n\n\n<h3 id=\"h-china-development-pipeline\" class=\"wp-block-heading\">China Development Pipeline<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase III:<\/strong> Osteosarcoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC)<\/li>\n\n\n\n<li><strong>Proof-of-Concept Studies:<\/strong> Head and neck cancer, prostate cancer, esophageal squamous cell carcinoma, colorectal cancer, and other solid tumors<\/li>\n\n\n\n<li><strong>Strategic Focus:<\/strong> Leveraging B7-H3&#8217;s broad expression profile across multiple tumor types<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-global-partnership-with-gsk\" class=\"wp-block-heading\">Global Partnership with GSK<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Deal Structure:<\/strong> Exclusive worldwide license granted to <strong>GlaxoSmithKline (GSK)<\/strong> in December 2023<\/li>\n\n\n\n<li><strong>Territory:<\/strong> Worldwide excluding Mainland China, Hong Kong, Macau, and Taiwan<\/li>\n\n\n\n<li><strong>Financial Terms:<\/strong> Up to $1.7 billion in upfront, milestone, and royalty payments<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Validates Hansoh&#8217;s ADC platform and provides non-dilutive funding for China development<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-implications\" class=\"wp-block-heading\">Market Implications<\/h2>\n\n\n\n<h3 id=\"h-osteosarcoma-treatment-landscape\" class=\"wp-block-heading\">Osteosarcoma Treatment Landscape<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unmet Need:<\/strong> Limited effective options for relapsed\/refractory osteosarcoma with poor prognosis<\/li>\n\n\n\n<li><strong>Patient Population:<\/strong> Approximately 1,000 new osteosarcoma cases annually in the US, with higher burden globally<\/li>\n\n\n\n<li><strong>Current Standard:<\/strong> Multi-agent chemotherapy with modest efficacy and significant toxicity<\/li>\n\n\n\n<li><strong>Commercial Opportunity:<\/strong> First-in-class B7-H3 ADC could capture significant market share in orphan indication<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-adc-competitive-positioning\" class=\"wp-block-heading\">ADC Competitive Positioning<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target Differentiation:<\/strong> B7-H3 represents emerging target with favorable safety profile compared to traditional ADC targets<\/li>\n\n\n\n<li><strong>Payload Advantage:<\/strong> Topoisomerase inhibitor payload offers proven cytotoxic mechanism with manageable toxicity<\/li>\n\n\n\n<li><strong>Platform Validation:<\/strong> Success validates Hansoh&#8217;s internal ADC discovery and development capabilities<\/li>\n\n\n\n<li><strong>Pipeline Leverage:<\/strong> Positive osteosarcoma data de-risks development in larger indications like NSCLC and SCLC<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-outlook\" class=\"wp-block-heading\">Strategic Outlook<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The positive Phase III results position Hansoh to:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Accelerate regulatory filings<\/strong> for osteosarcoma indication in China<\/li>\n\n\n\n<li><strong>Support GSK&#8217;s global development<\/strong> strategy with robust clinical data package<\/li>\n\n\n\n<li><strong>Expand proof-of-concept studies<\/strong> into additional B7-H3-expressing tumor types<\/li>\n\n\n\n<li><strong>Enhance valuation<\/strong> of remaining China rights ahead of potential commercial launch<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory approvals, and partnership outcomes. Actual results may differ due to regulatory decisions, competitive developments, and clinical trial variability.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026072800773_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026072800773_c.\"><\/object><a id=\"wp-block-file--media-855c8f78-70aa-423b-be5d-7b4bd3fcba92\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026072800773_c.pdf\">2026072800773_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026072800773_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-855c8f78-70aa-423b-be5d-7b4bd3fcba92\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Hansoh Pharmaceutical (HKG: 3692) announced that its pivotal Phase III ARTEMIS-011 clinical trial of Risvutatug&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[35,16,17,363,1182],"class_list":["post-70893","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-cancer","tag-clinical-trial-results","tag-hansoh-pharmaceutical","tag-hkg-3692"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hansoh Pharmaceutical&#039;s B7-H3 ADC Risvutatug Rezetecan Hits Primary Endpoint in Osteosarcoma Phase III Trial, Validating GSK Partnership - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hansoh Pharmaceutical (HKG: 3692) announced that its pivotal Phase III ARTEMIS-011 clinical trial of Risvutatug Rezetecan (HS-20093) achieved statistical significance for the primary endpoint of progression-free survival (PFS) in patients with relapsed or refractory osteosarcoma, representing a major milestone for the company&#039;s lead antibody-drug conjugate and validating its $1.7 billion partnership with GlaxoSmithKline.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70893\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hansoh Pharmaceutical&#039;s B7-H3 ADC Risvutatug Rezetecan Hits Primary Endpoint in Osteosarcoma Phase III Trial, Validating GSK Partnership\" \/>\n<meta property=\"og:description\" content=\"Hansoh Pharmaceutical (HKG: 3692) announced that its pivotal Phase III ARTEMIS-011 clinical trial of Risvutatug Rezetecan (HS-20093) achieved statistical significance for the primary endpoint of progression-free survival (PFS) in patients with relapsed or refractory osteosarcoma, representing a major milestone for the company&#039;s lead antibody-drug conjugate and validating its $1.7 billion partnership with GlaxoSmithKline.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70893\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-29T10:40:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70893#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70893\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hansoh Pharmaceutical&#8217;s B7-H3 ADC Risvutatug Rezetecan Hits Primary Endpoint in Osteosarcoma Phase III Trial, Validating GSK Partnership\",\"datePublished\":\"2026-07-29T10:40:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70893\"},\"wordCount\":528,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Cancer\",\"Clinical trial results\",\"Hansoh Pharmaceutical\",\"HKG: 3692\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70893#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70893\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70893\",\"name\":\"Hansoh Pharmaceutical's B7-H3 ADC Risvutatug Rezetecan Hits Primary Endpoint in Osteosarcoma Phase III Trial, Validating GSK Partnership - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-29T10:40:16+00:00\",\"description\":\"Hansoh Pharmaceutical (HKG: 3692) announced that its pivotal Phase III ARTEMIS-011 clinical trial of Risvutatug Rezetecan (HS-20093) achieved statistical significance for the primary endpoint of progression-free survival (PFS) in patients with relapsed or refractory osteosarcoma, representing a major milestone for the company's lead antibody-drug conjugate and validating its $1.7 billion partnership with GlaxoSmithKline.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70893#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70893\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70893#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hansoh Pharmaceutical&#8217;s B7-H3 ADC Risvutatug Rezetecan Hits Primary Endpoint in Osteosarcoma Phase III Trial, Validating GSK Partnership\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hansoh Pharmaceutical's B7-H3 ADC Risvutatug Rezetecan Hits Primary Endpoint in Osteosarcoma Phase III Trial, Validating GSK Partnership - Insight, China&#039;s Pharmaceutical Industry","description":"Hansoh Pharmaceutical (HKG: 3692) announced that its pivotal Phase III ARTEMIS-011 clinical trial of Risvutatug Rezetecan (HS-20093) achieved statistical significance for the primary endpoint of progression-free survival (PFS) in patients with relapsed or refractory osteosarcoma, representing a major milestone for the company's lead antibody-drug conjugate and validating its $1.7 billion partnership with GlaxoSmithKline.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70893","og_locale":"en_US","og_type":"article","og_title":"Hansoh Pharmaceutical's B7-H3 ADC Risvutatug Rezetecan Hits Primary Endpoint in Osteosarcoma Phase III Trial, Validating GSK Partnership","og_description":"Hansoh Pharmaceutical (HKG: 3692) announced that its pivotal Phase III ARTEMIS-011 clinical trial of Risvutatug Rezetecan (HS-20093) achieved statistical significance for the primary endpoint of progression-free survival (PFS) in patients with relapsed or refractory osteosarcoma, representing a major milestone for the company's lead antibody-drug conjugate and validating its $1.7 billion partnership with GlaxoSmithKline.","og_url":"https:\/\/flcube.com\/?p=70893","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-29T10:40:16+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70893#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70893"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hansoh Pharmaceutical&#8217;s B7-H3 ADC Risvutatug Rezetecan Hits Primary Endpoint in Osteosarcoma Phase III Trial, Validating GSK Partnership","datePublished":"2026-07-29T10:40:16+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70893"},"wordCount":528,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Cancer","Clinical trial results","Hansoh Pharmaceutical","HKG: 3692"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70893#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70893","url":"https:\/\/flcube.com\/?p=70893","name":"Hansoh Pharmaceutical's B7-H3 ADC Risvutatug Rezetecan Hits Primary Endpoint in Osteosarcoma Phase III Trial, Validating GSK Partnership - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-29T10:40:16+00:00","description":"Hansoh Pharmaceutical (HKG: 3692) announced that its pivotal Phase III ARTEMIS-011 clinical trial of Risvutatug Rezetecan (HS-20093) achieved statistical significance for the primary endpoint of progression-free survival (PFS) in patients with relapsed or refractory osteosarcoma, representing a major milestone for the company's lead antibody-drug conjugate and validating its $1.7 billion partnership with GlaxoSmithKline.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70893#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70893"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70893#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hansoh Pharmaceutical&#8217;s B7-H3 ADC Risvutatug Rezetecan Hits Primary Endpoint in Osteosarcoma Phase III Trial, Validating GSK Partnership"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70893","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70893"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70893\/revisions"}],"predecessor-version":[{"id":70895,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70893\/revisions\/70895"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70893"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70893"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70893"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}